DiaMedica Therapeutics

General Information

(Note: Not an IPO: “Although this is our initial public offering of our common shares in the United States, our common shares trade in Canada on the TSX Venture Exchange under the symbol “DMA” and over-the-counter in the United States on the OTCQB marketplace under the symbol “DMCAD.” The last reported sale price of our common shares at the close of business on November 27, 2018 on the TSX Venture Exchange was CAD $5.60 per share (US $4.21) and over-the-counter in the United States as quoted by the OTCQB marketplace was $4.22 per share.”)

We are a clinical stage biopharmaceutical company primarily focused on the development of novel recombinant (synthetic) proteins. Our goal is to use our patented and licensed technologies to establish our company as a leader in the development and commercialization of novel recombinant proteins to treat neurological and kidney diseases. Our primary focus is on acute ischemic stroke (“AIS”) and chronic kidney disease (“CKD”). We plan to advance our lead drug candidate, DM199, through clinical trials, as appropriate, to create shareholder value by establishing its clinical and commercial potential as a therapy for AIS and CKD.


Employees: 11
Founded: 2000
Contact Information
Address 2 Carlson Parkway, Suite 260 Minneapolis, MN 55447, US
Phone Number (763) 496-5454
Web Address http://www.diamedica.com
View Prospectus: DiaMedica Therapeutics
Financial Information
Market Cap $53.3mil
Revenues $0 mil (last 12 months)
Net Income $-4.5 mil (last 12 months)
IPO Profile
Symbol DMAC
Exchange NASDAQ
Shares (millions): 4.1
Price range $4.00 - $4.00
Est. $ Volume $16.4 mil
Manager / Joint Managers Craig-Hallum Capital Group
CO-Managers -
Expected To Trade: 12/7/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change